Homepage

Investing
in life.

Making
an impact.

Working
together.

Investing
in life.

Making
an impact.

Working
together.

Seroba is a leading European life sciences venture capital firm focused on value creation through backing winning innovations in biotech and medtech.

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that dosing is complete in Cohort 2 of the Opti-GAIN Phase I/II clinical trial of CTx001 in patients with GA secondary to AMD. The IDMC has completed its review of Cohorts 1 and 2 safety data, identified no significant safety concerns, and recommended that …

  • Therapeutics
Explore

Perfuze, a medical device company advancing stroke treatment through next-generation catheter technology, today announced publication of the final results of the MARRS pivotal study in the Journal of Neurointerventional Surgery. The trial met its primary endpoint, with successful reperfusion mTICI 2b-3 achieved in 89% of patients without rescue therapy – exceeding the prespecified performance goal. The study also demonstrated a 75% …

  • Medtech
Explore

Azafaros, a private company building a portfolio of disease-modifying therapeutics to become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. Azafaros’ NAVIGATE program consists of two global Phase 3 multi-centre, randomized, placebo-controlled studies designed to evaluate …

  • Therapeutics
Explore
Discover all news

Complementary skill sets with deep investment and operational industry experience. Seroba helps entrepreneurs create and build world class businesses around extraordinary science.

  • Venture partner

Jeanne Bolger
  • Accountant

Anita Dipalo
  • CFO
  • Partner

Andrew Duignan
  • Operations Manager

Ciara Green
  • Investment Analyst

Sophie Hughes
  • Investor relations
  • Partner

Maud Lazare
  • Partner

Jennifer McMahon
  • Partner

Bruno Montanari
  • Partner

Alan O’Connell
  • Partner

Daniel O’Mahony

A Portfolio of
Outstanding Companies
Discover full portfolio
Subscribe to our Newsletter
* = required field